Want to see IL:BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
4937.00
-217.00(-4.40%)
At close: 4:00 PM EDT
4937.00
-217.00(-4.40%)
Day’s Range― - ―
52-Week Range2,051.00 - 5,165.00
Previous CloseN/A
Volume80.50K
Average Volume (3M)85.46K
Market Cap
₪1.82B
Enterprise Value1.55K
Total Cash (Recent Filing)₪59.77M
Total Debt (Recent Filing)₪6.71M
Price to Earnings (P/E)66.9
Beta0.41
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding40,131,256
10 Day Avg. Volume88,081
30 Day Avg. Volume85,462
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.11
Price to Sales (P/S)6.62
P/FCF Ratio23.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Profitability & MarginsThe business has transitioned to durable profitability with very high gross margins and mid-teens net margins. Resistant gross margins reflect differentiated device economics and recurring consumables, enabling reinvestment in sales, R&D and clinical work while providing a margin buffer versus peers.
Installed Base Growth & Revenue VisibilityRapid unit placements and a growing installed base drive recurring consumable and service revenue, improving predictability. A $75M remaining performance obligation increases multi‑period revenue visibility, reducing near-term top‑line volatility and supporting expansion investments.
Conservative Balance Sheet And CashA strong cash position and minimal leverage provide financial flexibility to fund commercialization, strategic minority investments and pipeline work without near‑term refinancing risk. This conservatism supports sustained investment during reimbursement ramp periods.
Bears Say
Weakened Cash-Flow MomentumDespite reported profitability, declining free cash flow and operating cash below net income indicate working‑capital or timing pressures. Over multiple quarters this can constrain organic funding for growth, force slower rollouts, or require drawing on cash reserves for operations.
Dependence On Payer AdoptionCommercial upside for SWIFT protocols and wider Deep TMS use hinges on payer policy and actuarial decisions. Payer rollouts are multi‑quarter processes; delays or restrictive coverage limit patient access and utilization, slowing durable revenue gains despite clinical results.
Early-Stage Neurolief ExposureGrowth via Neurolief is contingent on milestone achievement and successful VA/IDN rollouts. BrainsWay’s exposure is financing‑based rather than equity ownership, so returns depend on a third party's execution; failure or delays could reduce expected strategic benefits and tie up capital.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was 2051.00 and its highest was 5165.00 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is ₪1.82B.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Nov 18, 2026 which is in 97 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Aug 12, 2026. The company reported 20 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,131,256 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of 20 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.753%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in IL:BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainsway Ltd
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's primary innovation is its Deep Transcranial Magnetic Stimulation (dTMS) platform, which offers treatment for disorders including major and anxious depression, obsessive-compulsive disorder, nicotine addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatric practitioners, hospitals, and medical centers across the United States, Europe, Israel, and other international markets.
BWAY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed strong operational and financial momentum: robust revenue growth (+35%), substantial margin and profitability expansion (operating income >300%, adjusted EBITDA +141%, margin expansion to 20%), growing installed base (+42% systems placed) and a larger, more visible backlog (+30% RPO). Clinical and reimbursement progress (SWIFT durability data, 57M covered lives, >83% PTSD response in a 462‑patient study) and strategic minority investments support a multi‑year growth thesis. Notable cautions include rising R&D and G&A spend, uneven reimbursement adoption across markets, conditionality/uncertainty around Neurolief and wide forecast ranges for margins/EBITDA, and revenue timing risk from backlog. On balance, positive operational trends, cash strength and improved visibility outweigh the highlighted risks.View all IL:BWAY earnings summaries